Ipilimumab
Ipilimumab is a monoclonal antibody used in cancer immunotherapy.
Ipilimumab is a monoclonal antibody used in cancer immunotherapy. It targets cytotoxic T-lymphocyte associated protein 4 (CTLA-4), an immune checkpoint receptor that normally dampens T-cell activation. By blocking CTLA-4, ipilimumab enhances antitumor immune responses and can promote cytotoxic T cell activity against malignant cells. It is therefore classified as an immune checkpoint inhibitor and is used primarily in combination regimens rather than as a conventional cytotoxic therapy.
Clinically, ipilimumab has been studied across multiple solid tumors, including melanoma, renal cell carcinoma, hepatocellular carcinoma, bladder cancer, uveal melanoma, and rare cancers with brain metastases. Recent research continues to evaluate its role in dual checkpoint inhibitor with nivolumab, as well as in combination with local or systemic therapies such as percutaneous hepatic perfusion, BRAF/MEK inhibitors, and (chemo)Radiotherapy. These studies reflect its ongoing importance in checkpoint inhibitor and in treatment strategies for metastatic disease, including brain metastases and liver-dominant tumors.
Where the papers sit
14 papers from the last 6 months study ipilimumab directly · updated from PubMed 6 Nov 2026
Study type 3 clinical trials · 4 observational · 4 human data · 2 preclinical · 1 unclassified
Themes 3 themes · 1 paradigm shift · 1 new direction
-
Checkpoint Response and Resistance
Immune checkpoint blockade is being tested across melanoma and less typical tumors, with nivolumab–ipilimumab responses tied to biomarkers and disease context. Melanoma brain metastases work compares dosing schedules, while Birt-Hogg-Dubé-associated angiomyolipoma and GIST reports extend interest beyond melanoma. Prostate cancer studies focus on immune biomarkers of response and resistance, and imatinib is examined as a partner in GIST. The evidence remains heterogeneous, favoring biomarker-guided combinations rather than a universal regimen.
5 papers · 35.7%
-
PD-L1 Combination Strategies
PD-1/PD-L1 combinations are being pushed into first-line treatment, especially for metastatic NSCLC with low PD-L1 expression. Nivolumab plus ipilimumab is weighed against early harm and benefit, while atezolizumab-bevacizumab-ipilimumab extends triplet testing to advanced HCC. Reviews emphasize combinations to counter PD-(L)1 resistance and reach rare cancers, but durable antibody delivery remains experimental. Clinical benefit, toxicity, and patient selection remain unresolved.
5 papers · 35.7%
-
Immunotherapy Outcomes and Cost
Renal cell carcinoma remains the main setting for first-line nivolumab plus ipilimumab, with clinical scores and cost-effectiveness analyses shaping treatment selection. Papillary RCC data test whether this regimen can displace standard care, while comparisons span pembrolizumab and toripalimab-based strategies. Real-world esophageal squamous cell carcinoma cohorts broaden the evidence beyond kidney cancer but do not establish a common benefit. The field is moving toward risk- and value-informed use, with efficacy and economic outcomes still variable.
4 papers · 28.6%
More intensive ipilimumab-based therapy is not uniformly beneficial and may add harm without improving disease control
The metastatic castration-resistant prostate cancer dose-escalation study found that higher ipilimumab doses produced disease control and CD8 activation similar to the lower-dose regimen but with a less favorable safety profile, while the metastatic non-small-cell lung cancer analysis found rapid progression in 40% of patients receiving nivolumab plus ipilimumab versus 26% with chemotherapy and identified clinical and immune features associated with early detriment. Together, these findings challenge the assumption that intensifying or selecting dual checkpoint blockade broadly improves outcomes: treatment intensity and immune activation do not ensure benefit, and some patients may be harmed or progress rapidly instead 42873849Oct 42360104Jun.
Ipilimumab becomes a continuously produced biologic rather than an intermittently administered checkpoint drug
The encapsulated cell-based “biologics factory” in immunocompetent mice treated ipilimumab as an antibody to be manufactured in situ, rather than as a drug delivered by repeated injection or infusion. The engineered allogeneic cell chassis produced ipilimumab among a diverse set of monoclonal antibodies, while an immunomodulatory alginate formulation reduced fibrosis and supported sustained antibody delivery. This places ipilimumab in a new therapeutic-delivery role: a single administration of antibody-producing cells could replace recurrent dosing and its associated peak–trough exposure and access problems 42826187Oct.
Papers
The 14 papers from the last 6 months that study ipilimumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Checkpoint Response and Resistance (5)
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer. Science advances · 14 Oct 2026 PMID 42873849
- Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases. European journal of cancer (Oxford, England : 1990) · 15 Sept 2026 PMID 42743884
- Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. Med (New York, N.Y.) · 20 Aug 2026 PMID 42624103
- Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma. Journal for immunotherapy of cancer · 29 Jul 2026 PMID 42527032
- Enhanced anti-tumor effects of Imatinib and immune checkpoint inhibitors on gastrointestinal stromal tumor cells (GISTs): insights from monoculture and 3D co-culture models. Medical oncology (Northwood, London, England) · 13 Jul 2026 PMID 42439972
PD-L1 Combination Strategies (5)
- Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies. Science advances · 2 Oct 2026 PMID 42826187
- Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. International journal of clinical oncology · 11 Aug 2026 PMID 42579028
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 Jun 2026 PMID 42360104
- Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. The lancet. Gastroenterology & hepatology · 22 Jun 2026 PMID 42330996
- Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
Immunotherapy Outcomes and Cost (4)
- Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
- Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study. Cancer immunology, immunotherapy : CII · 14 Jun 2026 PMID 42289036
- Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. European journal of cancer (Oxford, England : 1990) · 3 Jun 2026 PMID 42235464
- Three-factor Clinical Score for First-line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma. Anticancer research · 27 May 2026 PMID 42203341
By study type
Clinical trials (3)
- Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 Jun 2026 PMID 42360104
- Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. The lancet. Gastroenterology & hepatology · 22 Jun 2026 PMID 42330996
- Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. European journal of cancer (Oxford, England : 1990) · 3 Jun 2026 PMID 42235464
Observational studies and case reports (4)
- Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases. European journal of cancer (Oxford, England : 1990) · 15 Sept 2026 PMID 42743884
- Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. Med (New York, N.Y.) · 20 Aug 2026 PMID 42624103
- Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma. Journal for immunotherapy of cancer · 29 Jul 2026 PMID 42527032
- Three-factor Clinical Score for First-line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma. Anticancer research · 27 May 2026 PMID 42203341
Human data, design not indexed (4)
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer. Science advances · 14 Oct 2026 PMID 42873849
- Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
- Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. International journal of clinical oncology · 11 Aug 2026 PMID 42579028
- Combos New and Old Counter PD-(L)1 Resistance, Treat Rare Cancers. Cancer discovery · 4 Jun 2026 PMID 42240229
Preclinical: animal, cell and lab studies (2)
- Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies. Science advances · 2 Oct 2026 PMID 42826187
- Enhanced anti-tumor effects of Imatinib and immune checkpoint inhibitors on gastrointestinal stromal tumor cells (GISTs): insights from monoculture and 3D co-culture models. Medical oncology (Northwood, London, England) · 13 Jul 2026 PMID 42439972
Unclassified: not yet indexed with MeSH (1)
- Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study. Cancer immunology, immunotherapy : CII · 14 Jun 2026 PMID 42289036
Written from 14 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.